Cargando…

Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique survey

OBJECTIVES: The aim of the Patient preferences to Assess Value IN Gene therapies (PAVING) study was to investigate trade‐offs that adult Belgian people with haemophilia (PWH) A and B are willing to make when choosing between prophylactic factor replacement therapy (PFRT) and gene therapy. METHODS: T...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Overbeeke, Eline, Hauber, Brett, Michelsen, Sissel, Peerlinck, Kathelijne, Lambert, Catherine, Hermans, Cedric, Lê, Phu Quoc, Goldman, Michel, Simoens, Steven, Huys, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293173/ https://www.ncbi.nlm.nih.gov/pubmed/34472162 http://dx.doi.org/10.1111/hae.14401

Ejemplares similares

Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING study
por: van Overbeeke, Eline, et al.
Publicado: (2020)

Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in Hemophilia
por: van Overbeeke, Eline, et al.
Publicado: (2021)

Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives
por: van Overbeeke, Eline, et al.
Publicado: (2020)

Examining patient and professional perspectives in the UK for gene therapy in haemophilia
por: Woollacott, Ione, et al.
Publicado: (2022)

Patient Centricity in Patient Preference Studies: The Patient Perspective
por: van Overbeeke, Eline, et al.
Publicado: (2020)

Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies
por: Michelsen, Sissel, et al.
Publicado: (2020)

Pain and pain management in haemophilia
por: Auerswald, Günter, et al.
Publicado: (2016)

Haemophilia gene therapy: experiences and lessons from treated patients
por: Hermans, Cedric
Publicado: (2022)

Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review
por: Janssens, Rosanne, et al.
Publicado: (2019)

Patient Involvement in the Lifecycle of Medicines According to Belgian Stakeholders: The Gap Between Theory and Practice
por: Janssens, Rosanne, et al.
Publicado: (2018)

Pharmacokinetics in routine haemophilia clinical practice: rationale and modalities—a practical review
por: Hermans, Cedric, et al.
Publicado: (2020)

Emicizumab in acquired haemophilia A: about two clinical cases and literature review
por: Hansenne, Amandine, et al.
Publicado: (2021)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

Information needs of physicians regarding the diagnosis of rare diseases: a questionnaire-based study in Belgium
por: Vandeborne, Liese, et al.
Publicado: (2019)

How to translate and implement the current science of gene therapy into haemophilia care?
por: Hermans, Cedric, et al.
Publicado: (2023)

The Role of Physiotherapy in the New Treatment Landscape for Haemophilia
por: Lobet, Sébastien, et al.
Publicado: (2021)

Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study
por: van Overbeeke, Eline, et al.
Publicado: (2019)

Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US
por: Whichello, Chiara, et al.
Publicado: (2019)

Three-Dimensional Gait Analysis Can Shed New Light on Walking in Patients with Haemophilia
por: Lobet, Sébastien, et al.
Publicado: (2013)

Patient Preferences in Rare Diseases: A Qualitative Study in Neuromuscular Disorders to Inform a Quantitative Preference Study
por: Jimenez-Moreno, A. Cecilia, et al.
Publicado: (2021)

Correction to: Patient Preferences in Rare Diseases: A Qualitative Study in Neuromuscular Disorders to Inform a Quantitative Preference Study
por: Jimenez-Moreno, A. Cecilia, et al.
Publicado: (2021)

The Classification of Suspected Predominant Nociplastic Pain in People with Moderate and Severe Haemophilia: A Secondary Exploratory Study
por: Foubert, Anthe, et al.
Publicado: (2023)

ACTIVLIM‐Hemo: A new self‐reported, unidimensional and linear measure of activity limitations in persons with haemophilia
por: Lobet, Sébastien, et al.
Publicado: (2022)

R&D Costs of New Medicines: A Landscape Analysis
por: Simoens, Steven, et al.
Publicado: (2021)

Emerging Insights into European Markets of Biologics, Including Biosimilars
por: Simoens, Steven, et al.
Publicado: (2022)

Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients
por: Ljung, Rolf, et al.
Publicado: (2018)

Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA
por: Janssens, Rosanne, et al.
Publicado: (2019)

The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease
por: Henrard, Séverine, et al.
Publicado: (2014)

BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study
por: Santoro, Cristina, et al.
Publicado: (2020)

A study protocol for quantifying patient preferences in neuromuscular disorders: a case study of the IMI PREFER Project
por: Jimenez-Moreno, Aura Cecilia, et al.
Publicado: (2020)

Practical Implications From European Hospital Pharmacists on Prospective Risk Assessment for Medicine Shortages
por: Miljković, Nenad, et al.
Publicado: (2020)

Cross-cultural adaptation and validation of the Canadian Haemophilia Outcomes-Kids’ Life Assessment Tool (CHO-KLAT) in Côte d’Ivoire (the Ivory Coast)
por: Lambert, Catherine, et al.
Publicado: (2020)

Hæmophilia
Publicado: (1905)

Hæmophilia
por: Ruggles, S. D.
Publicado: (1902)

Hæmophilia
por: Porter, Charles A.
Publicado: (1900)

International consensus recommendations on the management of people with haemophilia B
por: Hart, Daniel P., et al.
Publicado: (2022)

European principles of inhibitor management in patients with haemophilia
por: Giangrande, P. L. F., et al.
Publicado: (2018)

Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis
por: Hermans, Cedric, et al.
Publicado: (2020)

Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma
por: Van Keer, Jan, et al.
Publicado: (2016)

Legg on Hæmophilia
Publicado: (1873)

Cannot write session to /tmp/vufind_sessions/sess_o72cdjc8m3jndvkgdarigj7loq